



New Approaches
New Medicines

Contacts:

Jeff Bacha
President and CEO
Inimex Pharmaceuticals
#604.225.2251

Kelley Childrey
Assistant Account Executive
Euro RSCG Life NRP
#415.901.3702

Inimex Pharmaceuticals Appoints Scientific and Medical Advisory Board

Vancouver, B.C., Canada – October 14, 2003 – Inimex Pharmaceuticals today announced the formation and appointment of its Scientific and Medical Advisory Board. The board, consisting of six international leaders from industry, academia, and medicine, will strengthen Inimex' position as a preeminent emerging biotechnology company working to develop novel drugs that have the potential to treat and prevent infections based on the selective augmentation of innate immunity.

“The members of our Scientific and Medical Advisory Board are a team of well-respected and influential individuals that will provide scientific and strategic input to our management team. We are honored to be working with such a distinguished group. Their insights and experience will be invaluable as we continue our pursuit of new medicines that harness host innate immunity to prevent and treat disease,” said Jeffrey Bacha, President and CEO of Inimex.

The recently formed Scientific and Medical Advisory Board is comprised of eminent scientists, academicians and physicians with experience across discovery research and drug development in the infectious disease area. Together they will consult and advise the research and development team at Inimex by bringing diverse scientific knowledge to the company. The appointed members are Anthony Chow, MD, PhD, Gordon Dougan, PhD, Stanley Falkow, PhD, B. Brett Finlay, PhD, Walter Singleton, MD, and H. Grant Stiver, MD.

Dr. Anthony Chow brings considerable clinical and regulatory expertise to the Board. Dr. Chow is a former member of the Antimicrobial Use and Clinical Trials Committee of the Infectious Disease Society of America and a past chair of the FDA Antibiotic Review Group. Dr. Chow has authored over 350 papers and book chapters on various aspects of infectious disease clinical syndromes, diagnosis, and treatment. He is currently Professor of Medicine and as Director of the MD Program at the University of British Columbia. He also serves as an attending physician in the Division of Infectious Diseases at the Vancouver Hospital Health Sciences Center and Director of the CIHR-UBC Strategic Training Program for Translational Research in Infectious Diseases. Dr. Chow received his MD degree from the University of Manitoba and completed a clinical and research fellowship in Infectious Diseases at Harbor-UCLA Medical Center.

Dr. Gordon Dougan is Director of the Centre for Molecular Microbiology and Infection at the Imperial College of Science, Technology and Medicine in London and a Rank Professor of Physiological Biochemistry. His research team studies enteric pathogens with a strong emphasis on basic pathogenic mechanisms and immunology. Throughout his career Dr. Dougan has served as a Professor, Lecturer, Referee, Advisor, and Board Member for



numerous respected institutions, universities, boards, committees, and organizations. Dr. Dougan currently sits as chairman of the New Vaccines Steering Committee for the World Health Organization. He received his PhD from the University of Sussex and conducted postdoctoral studies at the University of Washington.

Dr. Stanley Falkow is a world-renowned expert in cellular microbiology and microbial pathogenesis. He has published extensively and has received numerous awards for his achievements, including the Lifetime Achievement award from the American Society of Microbiology. Dr. Falkow is on the scientific advisory board of numerous successful biotechnology companies and is a member of the US National Academy of Sciences and the European Molecular Biology Organization. He is currently a Robert W. and Vivian K. Cahill Professor of Microbiology and Immunology at Stanford University, where he has taught since 1981. Prior to his tenure at Stanford, Dr. Falkow served as a Professor or Department Chief at medical schools and hospitals such as Georgetown, University of Washington, Truesdale Hospital, and Newport Hospital. He earned his PhD from Brown University in Rhode Island.

Dr. B. Brett Finlay is a co-founder of Inimex and a highly respected researcher in the field of host-pathogen interactions. Dr. Finlay has received numerous academic awards and is a Fellow of the Royal Society of Canada. Dr. Finlay's work was central to the development of the E. coli 0157 vaccine and he has recently been selected as Founding Director of the British Columbia SARS Accelerated Vaccine Initiative and as Co-Chair of the Scientific Advisory Committee of the Canadian SARS Research Consortium. Dr. Finlay is currently a Peter Wall Distinguished Professor at the University of British Columbia in the Department of Microbiology and Immunology and a Howard Hughes Medical Institute International Scholar. Dr. Finlay received his PhD from the University of Alberta and was a Postdoctoral Fellow at Stanford University School of Medicine.

Dr. Walter Singleton is a Senior Pharmaceutical Industry Executive with more than 20 years of experience managing preclinical and clinical development, in- and out-licensing of products, partnership negotiations, business development, and finance. Dr. Singleton was formerly Sr. Vice President for Medical & Pharmaceutical Development at Pfizer with responsibility for all clinical research and medical affairs function for the US Pharmaceuticals Division. In 1996, he founded New Drug Development Services, a technical consulting company, and served as President until 2000. He currently serves as Sr. Vice President of Medicine for Chugai Pharma USA, LLC in San Diego. Dr. Singleton received his MD from Oxford University Medical School.

Dr. H. Grant Stiver has been a pioneer of innovative management of infectious disease, including the practice of home self-administration of intravenous antibiotics. He has participated in numerous clinical trials evaluating the efficacy of antibacterial drugs and has an active clinical practice. Dr. Stiver is currently the Assistant Head of the Division of Infectious Disease at the University of British Columbia where he is also a Professor. Prior to his time at UBC, Dr. Stiver was Acting Head of the Section of Infectious Diseases and a Professor of Medicine and Medical Microbiology at the University of Manitoba where he earned his MD.



About Inimex Pharmaceuticals Inc.

Inimex Pharmaceuticals Inc. is a Vancouver, B.C. based biopharmaceutical company focused on the development of new medicines that utilize the innate immune response to prevent or treat human disease. For additional information, please visit the company's website, www.inimexpharma.com, or contact info@inimexpharma.com.

Certain statements in this announcement may contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.